Performance status-1 - Slightly symptomatic Posts on Medivizor
Navigation Menu

Performance status-1 – Slightly symptomatic Posts on Medivizor

Searching for patients with stage III non-small cell lung cancer to trial a biological treatment.

Searching for patients with stage III non-small cell lung cancer to trial a biological treatment.

Posted by on Sep 6, 2020 in Lung cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....

Read More

Looking for patients with newly-diagnosed multiple myeloma to trial a treatment combination

Looking for patients with newly-diagnosed multiple myeloma to trial a treatment combination

Posted by on Aug 30, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study is being carried out to examine whether KRD including carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Decadron) with or without daratumumab (Darzalex) is safe and effective in the treatment of multiple myeloma (MM). The main outcome to be measured is the measurable residual...

Read More

Looking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination

Looking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to assess the effectiveness of atezolizumab (Tecentriq) in combination with cabozantinib (Cabometyx) versus docetaxel (Taxotere) in patients with metastatic non-small cell lung cancer (NSCLC) which has previously been treated with immunotherapy and platinum-based chemotherapy....

Read More

Looking for patients with newly diagnosed multiple myeloma to test a combination therapy

Posted by on Oct 31, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is evaluating the safety and effectiveness of the D-KRd regimen (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in patients with multiple myeloma. The main outcome to be measured will be the number of patients who respond to treatment. This study is recruiting in Chicago, Illinois. The details Multiple myeloma (MM)...

Read More

Looking for patients with colorectal cancer to test a new therapy with tumor infiltrating lymphocytes

Posted by on Oct 31, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness of tumor-infiltrating lymphocytes (TIL) in the treatment of colorectal cancer. The main outcome to be measured is the tumor response to the treatment. This trial will be conducted in Texas, US. The details Cancer is one of the leading causes of death worldwide. Therapy such as...

Read More

Can adding chemotherapy agents to gefitinib improve outcomes for advanced NSCLC?

Posted by on Oct 28, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated whether adding chemotherapy agents to gefitinib (Iressa) improved outcomes for patients with advanced non-small cell lung cancer (NSCLC). This study found that this combination improved survival but increased side effects for these patients. Some background The gene for epidermal growth factor receptor...

Read More

Looking for patients with metastatic triple-negative breast cancer to trial experimental vaccine with biological therapy

Posted by on Sep 20, 2019 in Breast cancer | 0 comments

In a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...

Read More

Looking for patients with advanced colorectal cancer to test an experimental treatment

Posted by on Sep 10, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as colorectal cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More

Looking for patients with advanced triple negative breast cancer to test a new treatment

Posted by on Sep 10, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with solid tumors such as triple-negative breast cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More